Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1170
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained its Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $1060 to $1170.
June 25, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained its Buy rating on Regeneron Pharmaceuticals and increased the price target from $1060 to $1170, indicating strong confidence in the company's future performance.
The raised price target and maintained Buy rating from Argus Research suggest a positive outlook for Regeneron Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100